Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04993586Phase 1Completed

Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)

Role: lead

NCT04655625Phase 2Completed

Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)

Role: lead

NCT03263611Phase 1Completed

AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain

Role: lead

NCT04527081Phase 1Completed

Study of COVID-19 DNA Vaccine (AG0302-COVID19)

Role: lead

NCT04463472Phase 1Completed

Study of COVID-19 DNA Vaccine (AG0301-COVID19)

Role: lead

All 5 trials loaded